Medkart Launches India's First Tool to Find Substitute Medicine and Compare Prices, Transforming Access to Affordable Healthcare
In a significant stride towards affordable healthcare, Medkart Pharmacy has unveiled India's…
Government Push for Generic Drugs Finds Digital Ally in New Healthcare Portal
India's healthcare landscape is undergoing a significant transformation, led by national initiatives…
Medkart Introduces India's First Room-Temperature Stable Nicorandil Tablets, Enhancing Accessibility to Cardiac Care
In a country where cardiac care costs continue to burden millions, Medkart…
Not Just Pharmacy: How Medkart is Building India's Smartest Generic Medicine App
India’s pharmaceutical landscape is undergoing a vital transformation. Despite being home to…
Medkart Champions Generic Drug Quality Amid Rising Consumer Concerns
With growing scrutiny around the quality and reliability of generic medicines in…
Sandoz delivers strong H1 2025 results, with accelerated sales growth in the second quarter
Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules…
Zenara Pharma Receives U.S. FDA Approval for First Generic of Sertraline Hydrochloride Capsules with 180-Day CGT Exclusivity
HYDERABAD, India, August 1, 2025 /PRNewswire/ -- Zenara Pharma Private Limited ("Zenara"), a Biophore…
![Sandoz launches first and only interchangeable denosumab biosimilars in US, providing new affordable treatment options for over 10 million patients[1]](https://i0.wp.com/ml-eu.globenewswire.com/media/NjEzMmQ4NzAtZTBkMS00ZDhhLTkyYjgtOGM3YzY1ZWM5M2U5LTEwMTQyODItMjAyNS0wNi0wMi1lbg==/tiny/Sandoz-International-GmbH.png?w=420&resize=420,280&ssl=1 "Sandoz launches first and only interchangeable denosumab biosimilars in US, providing new affordable treatment options for over 10 million patients[1]")
Sandoz launches first and only interchangeable denosumab biosimilars in US, providing new affordable treatment options for over 10 million patients[1]
Ad-hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA…